Substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), cardiometabolic disorders, chronic kidney disease, COPD, pneumonia, liver failure, inflammatory bowel disease, liver cancer) all significantly declined
As an investigational triple-agonist, fully understanding its long-term cardiovascular, gastrointestinal, and pancreatic safety profile is essential before it can transition from a research setting to routine clinical practice. Dr
b , Cumulative food intake
The Advertising Standards Authority (ASA) has ruled against several weight loss patches making unsubstantiated claims, including rulings against slimming patches in 2020, 2022, and 2023
doi:10.3389/fphar.2025.1542269
While retatrutide is being developed primarily as an obesity and diabetes treatment, the triple-agonist mechanism has implications beyond weight loss